RED1,2,3: NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma. (Decision date - Oct 2017)
RED 1,2,3: NICE TA535 - lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine. (Decision date - September 2018) NHS England drug. To be used in line with NHS England commissioning intentions
RED: SSC2588: maintenance for adults with FLT3-internal tandem duplication (FLT3-ITD) acute myeloid leukaemia (AML) undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT) as per NHSE commissioning intentions. (Decision date - January 2024)